舍曲林治療青少年抑郁癥的開(kāi)放性研究

唐放放 陶領(lǐng)鋼 周鑫

[摘要] 目的 探討曲舍林治療青少年抑郁癥的臨床效果。 方法 方便選取2017年10月—2019年10月該院收治的94例青少年抑郁癥患者為研究對(duì)象，隨機(jī)分為實(shí)驗(yàn)組（口服曲舍林治療，47例）和對(duì)照組（口服氟西汀治療，47例），觀察兩組干預(yù)前后HAMD量表、BDI量表評(píng)分變化，以LOTCA量表評(píng)估認(rèn)知功能改善情況，PSQI量表評(píng)估睡眠改善情況，CGI量表評(píng)估兩組治療情況，另測(cè)定治療前后兩組血清CRP水平，統(tǒng)計(jì)不良反應(yīng)。 結(jié)果 兩組HAMD、BDI、LOTCA、CGI-SI、CGI-GI量表評(píng)分差異無(wú)統(tǒng)計(jì)學(xué)意義（P>0.05）;實(shí)驗(yàn)組治療后PSQI量表（5.0±1.7）分，CGI-EI評(píng)分（3.2±0.6）分，血CRP水平（3.7±1.6）g/L均優(yōu)于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（t=2.684、2.796、2.833，P<0.05）;實(shí)驗(yàn)組不良反應(yīng)率為4.26%，優(yōu)于對(duì)照組（χ2=3.411，P<0.05）。 結(jié)論 舍曲林治療青少年抑郁癥臨床效果確切，對(duì)改善患者睡眠、降低血清C反應(yīng)蛋白也具有積極作用，不良反應(yīng)少，安全性高，可作為青少年抑郁癥理想治療藥物加以推廣使用。

[關(guān)鍵詞] 青少年抑郁癥;曲舍林;療效;安全性

[中圖分類號(hào)] R749.4? ? ? ? ? [文獻(xiàn)標(biāo)識(shí)碼] A? ? ? ? ? [文章編號(hào)] 1674-0742（2020）10（b）-0112-03

[Abstract] Objective To explore the clinical effect of troseline in the treatment of adolescent depression. Methods A total of 94 adolescent depression patients admitted to the hospital from October 2017 to October 2019 were convenient selected as the research subjects， and they were randomly divided into an experimental group （oral troseline treatment， 47 cases） and a control group （oral fluoxetine treatment， 47 cases）， observe the changes in the scores of the HAMD scale and BDI scale before and after the intervention of the two groups， use the LOTCA scale to evaluate the improvement of cognitive function， the PSQI scale to evaluate the improvement of sleep， the CGI scale to evaluate the treatment of the two groups， and determine the before and after treatment The serum CRP levels of the two groups were counted for adverse reactions. Results There was no significant difference in HAMD， BDI， LOTCA， CGI-SI， CGI-GI scale scores between the two groups （P>0.05）; the experimental group had PSQI score （5.0±1.7）points after treatment， and CGI-EI score （3.2±0.6） points， blood CRP levels （3.7±1.6） g/L were better than those of the control group， the difference was statistically significant （t=2.684， 2.796， 2.833， P<0.05）; the adverse reaction rate of the experimental group was 4.26%， Better than the control group （χ2=3.411， P<0.05）. Conclusion Sertraline has a definite clinical effect in the treatment of adolescent depression. It also has a positive effect on improving patients' sleep and lowering serum C-reactive protein， with few adverse reactions and high safety. It can be promoted as an ideal treatment for adolescent depression.

[Key words] Juvenile depression; Traserin; Efficacy; Safety

受多種因素影響，我國(guó)抑郁癥患者數(shù)近年日漸增多，發(fā)病年齡也呈年輕化趨勢(shì)，青少年抑郁癥問(wèn)題受到廣泛重視。國(guó)內(nèi)一項(xiàng)中學(xué)生心理健康狀況調(diào)研數(shù)據(jù)顯示，中學(xué)生抑郁發(fā)生率高達(dá)25.5%～44%，其中構(gòu)成疾病者占比約20%，是中學(xué)生最主要的心理問(wèn)題之一[1]。此病在臨床表現(xiàn)為心情壓抑、不愉快，缺乏學(xué)習(xí)興趣和動(dòng)力，脾氣較差，易煩躁激惹，思維反應(yīng)慢，注意力不集中，伴睡眠障礙、軀體不適等，嚴(yán)重影響學(xué)生身心健康[2]。抗抑郁是臨床治療次病重要方法，但很多抗抑郁藥不適合青少年人群，可選擇的藥物種類不多，臨床用藥需謹(jǐn)慎[3]。曲舍林是臨床實(shí)踐證實(shí)的可安全用于青少年抑郁癥治療的藥物，該文方便選取2017年10月—2019年10月該院收治的94例抑郁癥患者為研究對(duì)象，探討其臨床療效，現(xiàn)報(bào)道如下。